Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Joe

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Cancer Research|May 3, 2008
Oncogene addictionI Bernard Weinstein, Andrew Joe
Future Oncology (London, England)|February 13, 2024
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring <i>NRG1</i> gene fusionsDong-Wan Kim, Alison M Schram, Antoine Hollebecque, et al.
Science (New York, N.Y.)|October 13, 2018
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapyRazvan Cristescu, Robin Mogg, Mark Ayers, et al.
Science (New York, N.Y.)|June 10, 2017
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockadeDung T Le, Jennifer N Durham, Kellie N Smith, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Cancer Research|May 3, 2008
Oncogene addictionI Bernard Weinstein, Andrew Joe
Future Oncology (London, England)|February 13, 2024
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring <i>NRG1</i> gene fusionsDong-Wan Kim, Alison M Schram, Antoine Hollebecque, et al.
Science (New York, N.Y.)|October 13, 2018
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapyRazvan Cristescu, Robin Mogg, Mark Ayers, et al.
Science (New York, N.Y.)|June 10, 2017
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockadeDung T Le, Jennifer N Durham, Kellie N Smith, et al.
Pageof 1